Can toxic bilirubin treat a variety of illnesses? | Science science.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.org Daily Mail and Mail on Sunday newspapers.
Guangzhou, January 15, 2021: New journal
BIO Integration (BIOI) publishes its fourth issue, volume 1, issue 4. BIOI is a peer-reviewed, open access, international journal, which is dedicated to spreading multidisciplinary views driving the advancement of modern medicine. Aimed at bridging the gap between the laboratory, clinic, and biotechnology industries, it will offer a cross-disciplinary platform devoted to communicating advances in the biomedical research field and offering insights into different areas of life science, in order to encourage cooperation and exchange among scientists, clinical researchers, and health care providers.
The issue contains an original article, three review articles, a mini review article and a commentary:
Nanotechnology Now
Abstract:
Announcing a new publication for BIO Integration journal. In this commentary the authors Phei Er Saw and Sangyong Jon from Sun Yat-Sen University, Guangzhou, China and the Korea Advanced Institute of Science and Technology, Daejeon, Korea, consider how the entry mechanism of nanoparticles into tumors determines the future direction of nanomedicine development.
Understanding nanoparticle entry mechanism into tumors
Guangzhou, China and Daejeon, Korea | Posted on December 25th, 2020
Enhanced permeability and retention (EPR) allows nanoparticles to passively accumulate at tumor sites via gaps between endothelial cells (inter-endothelial gaps) in tumor-associated blood vessels that have abnormal structural integrity with pores ranging in size from submicron to micron. The authors review future directions of nanomedicine development, focusing on the mechanism of nanoparticle entry into tumors instead of clinical transformation itself. Designing better nan
Researchers review future directions of nanomedicine development
Announcing a new publication for
BIO Integration journal. In this commentary the authors Phei Er Saw and Sangyong Jon from Sun Yat-Sen University, Guangzhou, China and the Korea Advanced Institute of Science and Technology, Daejeon, Korea, consider how the entry mechanism of nanoparticles into tumors determines the future direction of nanomedicine development.
Enhanced permeability and retention (EPR) allows nanoparticles to passively accumulate at tumor sites via gaps between endothelial cells (inter-endothelial gaps) in tumor-associated blood vessels that have abnormal structural integrity with pores ranging in size from submicron to micron.
The authors review future directions of nanomedicine development, focusing on the mechanism of nanoparticle entry into tumors instead of clinical transformation itself. Designing better nanoparticles to achieve efficient clinical transformation can be informed by a deep under
Announcing a new publication for
BIO Integration journal. In this commentary the authors Phei Er Saw and Sangyong Jon from Sun Yat-Sen University, Guangzhou, China and the Korea Advanced Institute of Science and Technology, Daejeon, Korea, consider how the entry mechanism of nanoparticles into tumors determines the future direction of nanomedicine development.
Enhanced permeability and retention (EPR) allows nanoparticles to passively accumulate at tumor sites via gaps between endothelial cells (inter-endothelial gaps) in tumor-associated blood vessels that have abnormal structural integrity with pores ranging in size from submicron to micron. The authors review future directions of nanomedicine development, focusing on the mechanism of nanoparticle entry into tumors instead of clinical transformation itself. Designing better nanoparticles to achieve efficient clinical transformation can be informed by a deep understanding of the mechanism of nanoparticle entry or the mode of act